Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer

Korean Journal of Urology

Volumn 53, Issue 9, 2012, Pages 607-613

  Hong, Seok Young ^a   Cho, Dae Sung ^b   Kim, Sun Il ^a   Ahn, Hyun Soo ^a   Kim, Se Joong ^a  

^a Ajou University School of Medicine   (South Korea)

^b Bundang Jesaeng Hospital   (South Korea)

Author keywords

Prognosis; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORCHIECTOMY; PROGRESSION FREE SURVIVAL; PROSTATE CANCER;

EID: 84866993517     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2012.53.9.607     Document Type: Article

References (29)

1. Kim SJ, Kim SI. Incidence, epidemiology and patterns of progression of prostate cancer. J Korean Med Assoc 2010;53:92-7.
2. Hori S, Jabbar T, Kachroo N, Vasconcelos JC, Robson CN, Gnanapragasam VJ. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol 2011;137:235-41.
3. Arai Y, Yoshiki T, Yoshida O. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 1990;144:1415-9.
4. Cooper EH, Armitage TG, Robinson MR, Newling DW, Richards BR, Smith PH, et al. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 1990;66(5 Suppl):1025-8.
5. Mulders PF, Fernandez del Moral P, Theeuwes AG, Oosterhof GO, van Berkel HT, Debruyne FM. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol 1992;21:2-5.
6. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280: 969-74.
7. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005;23:6992-8.
8. May M, Gunia S, Helke C, Braun KP, Pickenhain S, Hoschke B. Is it possible to provide a prognosis after radical prostatectomy for prostate cancer by means of a PSA regression model? Int J Biol Markers 2005;20:112-8.
9. King CR, Presti JC, Brooks JD, Gill H, Spiotto MT. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008;70:1472-7.
10. Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987;138:1181-4.
11. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992; 147(3 Pt 2):956-61.
12. Park YH, Hwang IS, Jeong CW, Kim HH, Lee SE, Kwak C. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. J Urol 2009;181:2520-4.
13. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002;168:995-1000.
14. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventos CX, et al. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer. Int J Biol Markers 2005;20:209-16.
15. Morote J, Trilla E, Esquena S, Abascal JM, Reventos J. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer 2004;108: 877-81.
16. Benaim EA, Pace CM, Lam PM, Roehrborn CG. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 2002;59:73-8.
17. Huang SP, Bao BY, Wu MT, Choueiri TK, Goggins WB, Huang CY, et al. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate 2011;71:1189-97.
18. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989;141: 1088-90.
19. Park BJ, Lee YG, Ahn HK. Prognostic significance of prostate-specific antigen level two months after maximal androgen blockade in metastatic prostate cancer. Korean J Urol 2003;44: 855-60.
20. Petros JA, Andriole GL. Serum PSA after antiandrogen therapy. Urol Clin North Am 1993;20:749-56.
21. Furuya Y, Akimoto S, Akakura K, Igarashi T, Murakami S, Shimazaki J, et al. Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. Urol Int 1998;60:28-32.
22. Park SC, Choi HY, Kim CS, Hong SJ, Kim WJ, Lee SE, et al. Predictive variables of the progression to androgen independent prostate cancer after combined androgen blockade. Korean J Urol 2007;48:408-15.
23. Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009;115:981-7.
24. Huang SP, Bao BY, Wu MT, Choueiri TK, Goggins WB, Liu CC, et al. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. Aging Male 2012;15:34-41.
25. Sasaki T, Onishi T, Hoshina A. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis 2011;14:248-52.
26. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24: 3984-90.
27. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005;23:6556-60.
28. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008;112: 1247-53.
29. Lee SY, Kim YS, Hong SJ. Clinical response of combined androgen blockade in metastatic prostate cancers. Korean J Urol 2000;41: 361-6.